آنتی ­بادی MLH1 (BS29)

Name: MLH1 Antibody Clone BS29

Description and aplications: MLH1 is a mismatch repair gene that is deficient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MLH1 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts. Along with PMS2, MSH2 and MSH6, MLH1 antibody is helpful in diagnosis of MSI. An IHC study conducted by Mayo clinic on 535 cases with MSI-high, 90% of the tumors showed loss of MLH1, MSH2 and/or MSH6 expression, while 70% of the remaining cases showed isolated loss of PMS2 expression. Endometrial carcinomas are the most common non-colorectal cancers occur in HNPCC. The most common IHC abnormality in endometrial carcinomas with MSI was concurrent loss of MLH1/PMS2. Adding of PMS2 and MSH6 to MLH1 and MSH2 antibodies increased sensitivity for diagnosis of MSI. Tumors with low-level MSI show unfavourable pathological characteristics compared to tumours with no and tumours with high-level MSI.

Composition: anti-human MLH1 mouse monoclonal antibody obtained from supernatant culture and prediluted in a tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.